Glycated Albumin Assay Market 2018 by its Scientific Reviews and Key Side-Effects till 2026
Glycation is the process of bonding of a sugar molecule. For instance, glucose to a protein or a lipid molecule such as albumin. Glycated albumin is glucose bonded to an albumin molecule. Protein molecule i.e. albumin is present in blood, major body organs, and in body fluids. Function of albumin is to maintain shape of the cell, distribution of hormones, and nutrients. The amount of albumin decreases in the body when blood glucose levels are low and the amount of albumin increases in the body when blood glucose levels are high. Glycated albumin is measured during initiation of diabetes therapies to determine medication dose for treatment of diabetes.
Request For a Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/1915
Glycated Albumin Assay Market Drivers:-
Approval of new products for detection of diabetes is expected to drive the global glycated albumin assay market growth. For instance, in 2011, Diazyme Laboratories, Enzymatic glycated serum protein (GSP, Glycated Albumin) Assay Kit was approved by the U.S. Food and Drug Administration (FDA). Enzymatic glycated serum protein (GSP, Glycated Albumin) Assay is two part liquid stable reagent, which can be used with various types of automated clinical chemistry analyzers. This product provides additional diagnostic values to clinical practices in diabetes management and screening. Thus, approval of products to manage diabetes in a rapid and accurate way is expected to drive glycated albumin assay market growth.
High prevalence of diabetes is expected to drive glycated albumin assay market growth. According to a survey conducted by National Institute of health (NIH), in 2016, more than 62 million people are diagnosed with diabetes in India.
Availability of alternative diabetes diagnosis method such as glucometer is expected to restrain the market growth. Furthermore, the vulnerability of variations offered by the test is also expected to decrease the adoption of glycated albumin assay, which in turn is restraining market growth
Purchase This Premium Report : https://www.coherentmarketinsights.com/insight/buy-now/1915
Glycated Albumin Assay Market Key Players:-
Key players operating in global glycated albumin assay market include Epinex Diagnostics Inc., Simes Sikma biotechnology Co. Ltd., Ningbo Purebio biotechnology Co. Ltd., Asahi Kasei Pharma Corpoation, Life Span Diabetes Clinic, Exocell Inc., Diazyme Laboratories, Maccura Biotechnology Co. Ltd., and Abnova Corporation.
Glycated Albumin Assay Market Taxonomy:-
By Product Type:-
- Glycated Albumin (human)
- Glycated Albumin (animals)
- Type 1 Diabetes
- Type 2 Diabetes
By End Users:-
- Diagnostic Centers
- Research Institutes
Glycated Albumin Assay Market Regional Analysis:-
North America is expected to dominate the Global Glycated Albumin Assay Market due to high prevalence of diabetes. According to a survey conducted by Center for disease control and prevention (CDC), in 2016, more than 30.3 million people in the U.S. are diagnosed with diabetes that accounts for around 9% of the U.S. population. More than 84.1 million people in U.S. are diagnosed with prediabetes. Such high prevalence of diabetes in U.S. is expected to boost growth of global glycated albumin assay market.
Asia Pacific glycated albumin assay market is expected to witness significant growth due to FDA approvals of products launched by key players in this market. For instance, in 2017, Asahi Kasei Pharma Corporation, manufacturer of pharmaceuticals and pharmaceutical intermediates, received an approval for their new product, Lucica glycated albumin –L. It is an in vitro diagnostic assay kits. Asahi Kasei Pharma Corporation leveraged its own original enzymes to develop glycated albumin assay kits for use with biochemical auto analyzer. Approval of new product to manage diabetes is expected to drive glycated albumin assay market growth.